
Shares of eye-drug developer Kodiak Sciences KOD.O down 4.4% in extended trading to $22 as it looks to raise equity
Palo Alto, California-based precommercial biotech commences 6 mln share offering
JP Morgan, Jefferies, Evercore and UBS are joint bookrunners
KOD shares fell for 5th-straight session on Mon, finishing down 3.3% at $23.02. But the stock has soared more than six-fold over the past six months
With ~53 mln shares outstanding, co has $1.2 bln market cap
Of 8 analysts covering KOD, recommendation breakdown is 5 "strong buy" or "buy", 2 "hold" and 1"sell"; median PT is $24, current LSEG data reflects